(19)
(11) EP 4 739 308 A1

(12)

(43) Date of publication:
13.05.2026 Bulletin 2026/20

(21) Application number: 24742216.5

(22) Date of filing: 05.07.2024
(51) International Patent Classification (IPC): 
A61K 31/397(2006.01)
A61P 25/28(2006.01)
 A61P 25/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/397; A61P 25/00; A61P 25/28
(86) International application number:
PCT/EP2024/069001
(87) International publication number:
WO 2025/008506 (09.01.2025 Gazette 2025/02)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 06.07.2023 EP 23183833

(71) Applicant: Integrative Research Laboratories Sweden AB
413 46 Göteborg (SE)

(72) Inventor:
  • WATERS, Nicholas
    413 19 Göteborg (SE)

(74) Representative: Potter Clarkson 
Chapel Quarter Mount Street
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)

   


(54) 3-(2,3-DIFLUOROPHENOXY)AZETIDINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR USE IN THE TREATMENT AND/OR PREVENTION OF PATHOLOGICAL APATHY